Infliximab (Remicade®) is a chimeric monoclonal antibody and used to treat auto- immune disorders. Infliximab reduces the amount of active human tumour necrosis factor alpha (hTNFα) in the body by binding to it and preventing it from signaling the receptors for TNFα on the surface of various cell types. TNFα is one of the key cytokines that triggers and sustains the inflammatory reactions. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis. BioVision’s BioSimTM Infliximab ELISA kit has been developed for specific quantification of Infliximab concentration in human serum or plasma with high sensitivity and reproducibility.
产品特点
• Easy, convenient, sensitive and time-saving method to measure the level of Infliximab in human serum and plasma.
• Detection Range: 0.1 - 3 μg/ml
• Sensitivity: 30 ng/ml
• Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
• Recovery rate: 85 – 115% with normal human serum samples with known concentrations
• Cross Reactivity: No significant cross-reactivity or interference with other proteins present in native human serum or other therapeutic immunoglobulins.
